(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 April 2012 (26.04.2012)

PCT

(10) International Publication Number
WO 2012/054523 A2

(51) International Patent Classification:
A61K 31/4709 (2006.01) *A61K 31/131* (2006.01)
A61K 31/704 (2006.01)

(21) International Application Number:
PCT/US2011/056766

(22) International Filing Date:
18 October 2011 (18.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/394,716 19 October 2010 (19.10.2010) US
61/430,914 7 January 2011 (07.01.2011) US

(71) Applicant *(for all designated States except US)*: **EL-CELYX THERAPEUTICS, INC.** [US/US]; 11995 El Camino Real, Suite 305, San Diego, CA 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARON, Alain, D.** [US/US]; 12863 Baywind Point, San Diego, CA 92130 (US). **BROWN, Martin, R.** [US/US]; 834 Tolita Avenue, Coronado, CA 92118 (US). **JONES, Christopher, R., G.** [US/US]; 13713 Freeport Road, San Diego, CA 92129 (US). **FINEMAN, Mark, S.** [US/US]; 12444 Oakfort Place, San Diego, CA 92130 (US).

(74) Agent: **GUISE, Jeffrey, W.**; 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES

FIGURE 2 E



(57) Abstract: Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.

WO 2012/054523 A2